211 related articles for article (PubMed ID: 26897499)
1. Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy.
Sivaraman A; Ordaz Jurado G; Cathelineau X; Barret E; Dell'Oglio P; Joniau S; Bianchi M; Briganti A; Spahn M; Bastian P; Chun J; Chlosta P; Gontero P; Graefen M; Jeffrey Karnes R; Marchioro G; Tombal B; Tosco L; van der Poel HH; Sanchez-Salas R
World J Urol; 2016 Oct; 34(10):1367-72. PubMed ID: 26897499
[TBL] [Abstract][Full Text] [Related]
2. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
3. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
[TBL] [Abstract][Full Text] [Related]
4. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.
Dell'Oglio P; Karnes RJ; Joniau S; Spahn M; Gontero P; Tosco L; Fossati N; Kneitz B; Chlosta P; Graefen M; Marchioro G; Bianchi M; Sanchez-Salas R; Karakiewicz PI; Poppel HV; Montorsi F; Briganti A;
Urol Oncol; 2016 May; 34(5):234.e13-9. PubMed ID: 26706120
[TBL] [Abstract][Full Text] [Related]
5. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.
Abdollah F; Sun M; Schmitges J; Thuret R; Bianchi M; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
J Urol; 2012 Jul; 188(1):73-83. PubMed ID: 22578732
[TBL] [Abstract][Full Text] [Related]
6. Impact of Charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy: a competing risk regression analysis.
Lee JY; Lee DH; Cho NH; Rha KH; Choi YD; Hong SJ; Yang SC; Cho KS
Ann Surg Oncol; 2014 Feb; 21(2):677-83. PubMed ID: 24145996
[TBL] [Abstract][Full Text] [Related]
7. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
Briganti A; Joniau S; Gontero P; Abdollah F; Passoni NM; Tombal B; Marchioro G; Kneitz B; Walz J; Frohneberg D; Bangma CH; Graefen M; Tizzani A; Frea B; Karnes RJ; Montorsi F; Van Poppel H; Spahn M
Eur Urol; 2012 Mar; 61(3):584-92. PubMed ID: 22153925
[TBL] [Abstract][Full Text] [Related]
8. Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy.
Lee JY; Lee DH; Cho NH; Rha KH; Choi YD; Hong SJ; Yang SC; Cho KS
Yonsei Med J; 2014 Mar; 55(2):316-23. PubMed ID: 24532498
[TBL] [Abstract][Full Text] [Related]
9. Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.
Abdollah F; Dalela D; Sood A; Sammon J; Jeong W; Beyer B; Fossati N; Rogers CG; Diaz-Insua M; Peabody J; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
World J Urol; 2016 Oct; 34(10):1357-66. PubMed ID: 26873596
[TBL] [Abstract][Full Text] [Related]
10. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
[TBL] [Abstract][Full Text] [Related]
11. Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identification of risk categories according to number of positive nodes and Gleason score.
Schiavina R; Borghesi M; Brunocilla E; Manferrari F; Fiorentino M; Vagnoni V; Baccos A; Pultrone CV; Rocca GC; Rizzi S; Martorana G
BJU Int; 2013 Jun; 111(8):1237-44. PubMed ID: 23331345
[TBL] [Abstract][Full Text] [Related]
12. Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram.
Abdollah F; Klett DE; Sood A; Sammon JD; Pucheril D; Dalela D; Diaz M; Peabody JO; Trinh QD; Menon M
BJU Int; 2015 Nov; 116(5):703-12. PubMed ID: 25413443
[TBL] [Abstract][Full Text] [Related]
13. Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses.
Koo KC; Cho JS; Bang WJ; Lee SH; Cho SY; Kim SI; Kim SJ; Rha KH; Hong SJ; Chung BH
Cancer Res Treat; 2018 Jan; 50(1):129-137. PubMed ID: 28279064
[TBL] [Abstract][Full Text] [Related]
14. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
15. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
16. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
[TBL] [Abstract][Full Text] [Related]
17. Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification.
Briganti A; Gallina A; Suardi N; Capitanio U; Tutolo M; Bianchi M; Passoni N; Salonia A; Colombo R; Di Girolamo V; Guazzoni G; Rigatti P; Montorsi F
J Sex Med; 2010 Jul; 7(7):2521-31. PubMed ID: 20487236
[TBL] [Abstract][Full Text] [Related]
18. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival of patients aged 80 years or older treated with radical prostatectomy for prostate cancer.
Dell'Oglio P; Zaffuto E; Boehm K; Trudeau V; Larcher A; Tian Z; Moschini M; Shariat SF; Graefen M; Saad F; Capitanio U; Briganti A; Montorsi F; Karakiewicz PI
Eur J Surg Oncol; 2017 Aug; 43(8):1581-1588. PubMed ID: 28330822
[TBL] [Abstract][Full Text] [Related]
20. Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer.
Servoll E; Saeter T; Vlatkovic L; Lund T; Nesland J; Waaler G; Axcrona K; Beisland HO
BJU Int; 2012 May; 109(10):1489-94. PubMed ID: 21933333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
